RHHBY Stock Recent News

A Roche-Lilly collaboration to test for indications of Alzheimer's disease won FDA Breakthrough Device Designation on Thursday. The new test will now proceed to clinical trials needed for full FDA approval.

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.

The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.